California State Teachers Retirement System cut its holdings in MEDNAX Inc (NYSE:MD) by 2.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 151,351 shares of the company’s stock after selling 4,568 shares during the quarter. California State Teachers Retirement System owned approximately 0.16% of MEDNAX worth $8,420,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in MD. Sandy Spring Bank bought a new position in MEDNAX in the first quarter worth about $176,000. Blair William & Co. IL bought a new position in MEDNAX in the first quarter worth about $211,000. Brown Advisory Inc. bought a new position in MEDNAX in the fourth quarter worth about $231,000. Macquarie Group Ltd. raised its holdings in MEDNAX by 36.1% in the fourth quarter. Macquarie Group Ltd. now owns 4,900 shares of the company’s stock worth $262,000 after purchasing an additional 1,300 shares in the last quarter. Finally, C M Bidwell & Associates Ltd. bought a new position in MEDNAX in the first quarter worth about $278,000. 97.02% of the stock is owned by institutional investors.
In related news, CFO Vivian Lopez-Blanco sold 13,942 shares of the stock in a transaction that occurred on Tuesday, June 12th. The shares were sold at an average price of $46.46, for a total value of $647,745.32. Following the transaction, the chief financial officer now owns 100,590 shares in the company, valued at approximately $4,673,411.40. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider John C. Pepia sold 3,000 shares of the stock in a transaction that occurred on Tuesday, May 22nd. The stock was sold at an average price of $46.43, for a total transaction of $139,290.00. Following the completion of the transaction, the insider now owns 39,716 shares in the company, valued at approximately $1,844,013.88. The disclosure for this sale can be found here. In the last quarter, insiders sold 75,251 shares of company stock worth $3,462,384. 2.40% of the stock is owned by corporate insiders.
MEDNAX opened at $43.37 on Friday, according to Marketbeat Ratings. MEDNAX Inc has a 52-week low of $40.56 and a 52-week high of $63.04. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.74 and a current ratio of 1.74. The stock has a market cap of $4.18 billion, a PE ratio of 13.77, a P/E/G ratio of 1.12 and a beta of 0.24.
MEDNAX (NYSE:MD) last posted its quarterly earnings data on Monday, April 30th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.82 by $0.07. MEDNAX had a net margin of 9.34% and a return on equity of 10.13%. The firm had revenue of $901.90 million for the quarter, compared to the consensus estimate of $903.75 million. During the same quarter in the prior year, the company posted $0.75 earnings per share. The company’s revenue for the quarter was up 7.9% compared to the same quarter last year. analysts anticipate that MEDNAX Inc will post 3.94 earnings per share for the current fiscal year.
A number of brokerages have commented on MD. TheStreet upgraded shares of MEDNAX from a “c+” rating to a “b” rating in a report on Monday, March 12th. ValuEngine downgraded shares of MEDNAX from a “sell” rating to a “strong sell” rating in a report on Wednesday, May 2nd. Zacks Investment Research downgraded shares of MEDNAX from a “hold” rating to a “sell” rating in a report on Wednesday, April 11th. Credit Suisse Group cut their price objective on shares of MEDNAX to $57.00 and set a “neutral” rating on the stock in a report on Monday, May 7th. Finally, Jefferies Financial Group set a $58.00 price objective on shares of MEDNAX and gave the company a “hold” rating in a report on Thursday, March 15th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $55.92.
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.